

Contents

Abbreviations	xiv
Preface	xix
1 General principles	1
1.1 Introduction	1
1.2 What is cancer?	1
1.3 The cell cycle	2
1.4 Apoptosis	4
1.5 Chromosomes and cancer	6
1.6 Inherited vs. sporadic cancer	6
1.7 The multistage nature of cancer development	10
References	10
2 Oncogenes	12
2.1 Viruses and cancer	12
2.2 Cellular oncogenes	13
2.2.1 <i>Function of the proto-oncogenes</i>	16
2.2.2 <i>Mechanisms of oncogene activation</i>	26
2.3 Oncogenes in human tumors	29
References	10
3 Tumor suppressor genes	33
3.1 Introduction	33
3.2 Evidence for the existence of tumor suppressor genes	35
3.2.1 <i>Suppression of malignancy by cell fusion</i>	35
3.2.2 <i>Tumor suppressor genes in hereditary cancers: the retinoblastoma model</i>	36
3.3 Retinoblastoma— <i>RBI</i>	39

3.3.1	<i>Cell cycle regulation of RB</i>	40
3.3.2	<i>RB/E2F pathway</i>	41
3.3.3	<i>RB and apoptosis</i>	42
3.3.4	<i>RB in human cancers</i>	43
3.4	<i>TP53 (p53)</i>	44
3.4.1	<i>The TP53 gene and its protein product p53</i>	44
3.4.2	<i>Activation of TP53</i>	45
3.4.3	<i>Activated p53 responses—cell cycle inhibition</i>	47
3.4.4	<i>Activated p53 responses—apoptosis</i>	48
3.4.5	<i>Other functions of activated p53</i>	48
3.4.6	<i>Mutations of p53</i>	49
3.5	<i>APC</i>	50
3.5.1	<i>The APC gene and its protein product</i>	50
3.5.2	<i>Function of the APC protein</i>	51
3.5.3	<i>Mutations in APC</i>	53
3.6	<i>BRCA1 and BRCA2</i>	53
3.6.1	<i>The BRCA1 and 2 genes and their protein products</i>	54
3.6.2	<i>Mutations in BRCA1 and 2</i>	56
3.7	<i>WT1</i>	56
3.8	<i>NF1 and NF2</i>	57
3.8.1	<i>NF1</i>	57
3.8.2	<i>NF2</i>	58
3.9	<i>VHL</i>	59
3.10	<i>TSC1 and TSC2</i>	59
3.11	<i>PTCH</i>	60
3.12	<i>Interaction and differences between oncogenes and tumor suppressor genes</i>	60
	<i>References</i>	61
4	Cell cycle control genes and mismatch repair genes	64
4.1	<i>Introduction</i>	64
4.2	<i>Cyclins and cyclin-dependent kinases</i>	64

4.3	Cyclin-dependent kinase inhibitors	67
4.4	Progression and control of the cell cycle	68
4.5	Cyclins, CDKs and CKIs in cancer	71
4.6	Mismatch repair genes	72
	References	75
5	Hereditary cancers	77
5.1	Introduction	77
5.2	Inherited cancer syndromes	77
5.3	Procedures for genetic testing	78
5.4	Familial colon cancer	78
5.4.1	<i>Familial adenomatous polyposis (FAP)</i>	79
5.4.2	<i>Hereditary nonpolyposis colon cancer (HNPCC)</i>	82
5.4.3	<i>Other syndromes predisposing to colorectal cancer</i>	85
5.5	Familial breast and breast/ovarian cancer	87
5.5.1	BRCA1 and BRCA2	87
5.5.2	<i>Other syndromes predisposing to breast cancer</i>	89
5.6	Li-Fraumeni syndrome (LFS)	90
5.7	Multiple endocrine neoplasia	90
5.7.1	<i>Multiple endocrine neoplasia type 1 (MEN1)</i>	90
5.7.2	<i>Multiple endocrine neoplasia type 2 (MEN2)</i>	91
5.8	Von Hippel Lindau syndrome (VHL)	92
5.9	Familial renal cell cancer	92
5.10	Familial paraganglioma	93
5.11	Neurofibromatosis	93
5.11.1	<i>Neurofibromatosis type 1 (NF1)</i>	93
5.11.2	<i>Neurofibromatosis type 2 (NF2)</i>	94
5.12	Gorlin syndrome	95
5.13	Tuberous sclerosis	96
5.14	Familial gastric cancer	96
5.15	Familial melanoma	97

5.16	Hereditary prostate cancer	98
5.17	Conclusion	98
	References	98
6	Lung cancer	102
6.1	Introduction	102
6.2	Pathology	102
6.2.1	<i>Small-cell lung cancer (SCLC)</i>	103
6.2.2	<i>Nonsmall-cell lung cancer (NSCLC)</i>	103
6.3	Clinical features	107
6.4	Genetic factors and individual susceptibility	107
6.5	Molecular alterations in lung cancer	108
6.6	Tumor suppressor genes	109
6.7	Oncogenes	111
6.8	Growth factors and receptors	111
6.9	Mesothelioma	112
6.10	Multiple primary tumors of the upper aerodigestive tract	112
6.11	Implications for therapy	112
	References	113
7	Colorectal cancer	115
7.1	Introduction	115
7.2	The adenoma-carcinoma sequence	115
7.3	Genetic changes in sporadic colorectal cancer—the role of oncogenes	117
7.3.1	MYC	117
7.3.2	RAS	118
7.3.3	<i>Other oncogenes</i>	119
7.4	Genetic changes in sporadic colorectal cancer—the role of tumor suppressor genes	120
7.4.1	p53	120
7.4.2	<i>Adenomatous polyposis coli gene (APC)</i>	121
7.4.3	SMAD	122
7.4.4	MCC	123

7.4.5	NM23	123
7.4.6	<i>Other changes</i>	123
7.5	Mismatch repair defects	123
7.6	TGF	124
7.7	Cell cycle regulators	124
	References	125
8	Gastrointestinal cancer	128
8.1	Introduction	128
8.2	Pathology of esophagogastric cancer	128
8.2.1	<i>Esophageal cancer</i>	128
8.2.2	<i>Barrett's esophagus</i>	129
8.2.3	<i>Gastric cancer</i>	130
8.3	Epidemiology of esophagogastric malignancy	130
8.4	Cellular and molecular alterations in esophagogastric cancer	132
8.4.1	<i>Cell cycle regulation</i>	133
8.4.2	<i>Epithelial proliferation markers</i>	133
8.4.3	<i>Aneuploidy</i>	134
8.4.4	<i>Chromosomal aberrations</i>	134
8.4.5	<i>Loss of heterozygosity</i>	134
8.5	Tumor suppressor genes	135
8.5.1	p53	135
8.5.2	<i>Retinoblastoma (RB)</i>	137
8.5.3	p16	138
8.5.4	p14	138
8.5.5	<i>Fragile histidine triad (FHIT) gene</i>	138
8.5.6	<i>Adenomatous polyposis coli (APC) gene</i>	139
8.6	Growth factors and receptors	139
8.7	Oncogenes	140
8.7.1	<i>Cyclin D1</i>	140
8.7.2	RAS	140

8.8	DNA repair-associated genes	140
8.8.1	<i>Microsatellite instability</i>	141
8.9	Hereditary factors	141
8.10	Cancers of the small intestine	142
8.11	Pancreatic cancer	142
8.12	Hepatobiliary cancer	143
8.12.1	<i>Hepatocellular carcinoma</i>	143
8.12.2	<i>Intrahepatic cholangiocarcinoma</i>	143
8.12.3	<i>Extrahepatic bile duct and gallbladder cancer</i>	144
8.12.4	<i>Hepatoblastoma</i>	144
	References	144
9	Breast cancer	148
9.1	Introduction	148
9.2	Genetic changes in breast cancer	149
9.2.1	MYC	149
9.2.2	ERBB2 and RAS	151
9.2.3	p53	153
9.2.4	BRCA1 and BRCA2	155
9.2.5	CCND1	158
9.2.6	RB1	158
9.2.7	<i>Other chromosomal abnormalities and potential tumor suppressors</i>	158
9.3	Estrogens and cell cycle regulation	159
9.4	Male breast cancer	160
9.5	Gene expression profiling	160
	References	161
10	Genitourinary cancer	164
10.1	Ovarian and endometrial cancers	164
10.2	Cervical cancer	168
10.3	Testicular cancer	170
10.4	Renal cell cancer and bladder cancer	170

10.5	Prostate cancer	174
	References	176
11	Leukemia and lymphoma	180
11.1	Introduction	180
11.2	<i>TEL/JAK2</i>	182
11.3	<i>MYC</i>	182
11.4	<i>BCL1</i> and <i>BCL2</i>	184
11.5	<i>ABL/BCR</i>	185
11.6	<i>AML1/CBF /ETO(MTG8)</i>	188
11.7	<i>TLS/ERG</i>	189
11.8	<i>PML/RAR</i>	189
11.9	<i>ALL-1</i> and 11q23 translocations	190
11.10	<i>RB1</i> T cell oncogenes	190
11.11	Cyclin-dependent kinase 4 inhibitor, <i>CDKN2 (p16/MTS1/INK4a)</i>	190
11.12	<i>RAS</i>	191
11.13	<i>p53</i>	191
11.14	<i>MDM2</i>	192
11.15	Detection of minimal residual disease (MRD)	192
11.16	Refining the classification of leukemias and lymphomas	194
	References	196
12	Childhood solid tumors	198
12.1	Introduction	198
12.2	Retinoblastoma	198
12.3	Wilms' tumor	199
12.4	Neuroblastoma	201
12.5	Rhabdomyosarcoma	204
12.6	Ewing's sarcoma	206
	References	207
13	Therapeutic applications	209
13.1	Introduction	209

13.2	Receptors as targets	209
13.2.1	<i>Receptor tyrosine kinases—ERBB</i>	209
13.2.2	<i>BCR-ABL</i>	210
13.2.3	<i>Estrogen receptor (ER)</i>	211
13.2.4	<i>Retinoic acid receptor (RAR) and retinoid X receptor (RXR)</i>	211
13.2.5	<i>Peroxisome proliferator-activated receptor (PPAR)</i>	212
13.3	Immunologic intervention	212
13.3.1	<i>Vaccines</i>	212
13.3.2	<i>Antibodies</i>	216
13.3.3	<i>Immune cells</i>	219
13.3.4	<i>Cytokines</i>	221
13.4	Other targets	222
13.4.1	<i>Proteasomes</i>	222
13.4.2	<i>p53</i>	222
13.4.3	<i>Raf kinases</i>	224
13.4.4	<i>Cyclin-dependent kinases (CDKs)</i>	224
13.4.5	<i>Angiogenesis</i>	225
13.4.6	<i>Epigenetic silencing</i>	227
13.4.7	<i>Mitochondria</i>	228
13.4.8	<i>Carbohydrates</i>	228
13.4.9	<i>Cyclooxygenase 2 (COX-2)</i>	229
13.5	Antisense RNA or oligonucleotides	229
13.6	RNA interference/inhibition (RNAi)	231
13.7	Gene therapy	231
13.8	Drug discovery and drug design	235
13.9	Conclusions and future prospects	235
	References	237
14	Molecular techniques for analysis of genes	241
14.1	Introduction	241
14.2	Analysis of DNA or RNA	242

14.2.1	<i>Genetic markers</i>	242
14.2.2	<i>Polymerase chain reaction (PCR)</i>	243
14.2.3	<i>Mutation detection techniques</i>	244
14.2.4	<i>Southern blotting</i>	253
14.2.5	<i>Gene tracking with RFLPs and microsatellites</i>	255
14.2.6	<i>Single nucleotide polymorphisms (SNPs)</i>	257
14.2.7	<i>Northern blotting</i>	259
14.2.8	<i>In situ hybridization</i>	259
14.2.9	<i>Comparative genomic hybridization</i>	259
14.2.10	<i>DNA microarrays</i>	260
14.2.11	<i>Real-time (kinetic) RT-PCR</i>	261
14.3	<i>Analysis of proteins</i>	263
14.3.1	<i>Production of antibodies to onco- or tumor suppressor proteins</i>	264
14.3.2	<i>Western blotting</i>	265
14.3.3	<i>Immunohistochemical techniques</i>	265
14.3.4	<i>Flow cytometry</i>	266
14.3.5	<i>Proteomics</i>	267
14.3.6	<i>Tissue microarrays</i>	270
	References	270
	Index	272